Literature DB >> 21600528

Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Matthew K Ito1, Mary P McGowan, Patrick M Moriarty.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21600528     DOI： 10.1016/j.jacl.2011.04.001

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN： 1876-4789            Impact factor:   4.766


× No keyword cloud information.
  20 in total

Review 1.  The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.

Authors:  Anandita Agarwala; Peter Jones; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2015-01       Impact factor: 5.113

Review 2.  Familial hypercholesterolemia.

Authors:  Victoria Enchia Bouhairie; Anne Carol Goldberg
Journal:  Cardiol Clin       Date:  2015-05       Impact factor: 2.213

3.  PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.

Authors:  Maciej Banach; Piotr Jankowski; Jacek Jóźwiak; Barbara Cybulska; Adam Windak; Tomasz Guzik; Artur Mamcarz; Marlena Broncel; Tomasz Tomasik; Jacek Rysz; Agnieszka Jankowska-Zduńczyk; Piotr Hoffman; Agnieszka Mastalerz-Migas
Journal:  Arch Med Sci       Date:  2016-12-19       Impact factor: 3.318

4.  Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre.

Authors:  Agnieszka Mickiewicz; Justyna Borowiec-Wolna; Witold Bachorski; Natasza Gilis-Malinowska; Rafał Gałąska; Grzegorz Raczak; Magdalena Chmara; Bartosz Wasąg; Miłosz J Jaguszewski; Marcin Fijałkowski; Marcin Gruchała
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

5.  Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia.

Authors:  Elaine Wong; Tamara Goldberg
Journal:  P T       Date:  2014-02

Review 6.  Recommendations for the management of patients with familial hypercholesterolemia.

Authors:  David I Feldman; Michael J Blaha; Raul D Santos; Steve R Jones; Roger S Blumenthal; Peter P Toth; Laurence S Sperling; Seth S Martin
Journal:  Curr Atheroscler Rep       Date:  2015-01       Impact factor: 5.113

7.  The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.

Authors:  C Stefanutti; D J Blom; M R Averna; E A Meagher; H dT Theron; A D Marais; R A Hegele; C R Sirtori; P K Shah; D Gaudet; G B Vigna; B S Sachais; S Di Giacomo; A M E du Plessis; L T Bloedon; J Balser; D J Rader; M Cuchel
Journal:  Atherosclerosis       Date:  2015-03-14       Impact factor: 5.162

Review 8.  Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances.

Authors:  Claudia Stefanutti; Gilbert R Thompson
Journal:  Curr Atheroscler Rep       Date:  2015-01       Impact factor: 5.113

Review 9.  The need for combination drug therapies in patients with complex dyslipidemia.

Authors:  James Barnett; Adie Viljoen; Anthony S Wierzbicki
Journal:  Curr Cardiol Rep       Date:  2013-08       Impact factor: 2.931

10.  How Do PCSK9 Inhibitors Stack Up to Statins for Low-Density Lipoprotein Cholesterol Control?

Authors:  Marj P Zimmerman
Journal:  Am Health Drug Benefits       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.